{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:14:13Z","timestamp":1784121253980,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Entresto (sacubitril\/valsartan) is used to treat symptomatic chronic heart failure with reduced ejection fraction. Given its high potential budget impact, the Health Services Executive introduced a reimbursement application system (RAS) to ensure its appropriate use. The aim of this study was to evaluate the utilisation of Entresto in Ireland and compare patient characteristics to those of the pivotal PARADIGM\u2010HF trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used dispensed claims data from the Primary Care Reimbursement Services, clinical data obtained from the RAS, and data from published studies of Entresto utilisation. Differences in the baseline characteristics in the study populations <jats:italic>vs<\/jats:italic> the Entresto arm of the PARADIGM\u2010HF trial were analysed. We also investigated cardiovascular medication use in the 6 months pre\u2010 and post\u2010Entresto initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 2018, there were 1043 individuals receiving Entresto, corresponding to an expenditure of \u20ac1.2 million. Patients prescribed Entresto in Ireland were older, had lower left ventricular ejection fraction and were more symptomatic than those in the PARADIGM\u2010HF trial. Irish patient characteristics were reflective of Entresto\u2010treated populations in other real\u2010world studies. More than 63% of patients were commenced on the lowest Entresto dose. Entresto initiation was associated with a reduction in the use of other medications for heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The utilisation of Entresto has been steadily increasing in Ireland since its reimbursement approval. The expenditure in the first year was substantially lower than predicted, and the RAS is an example of how health technology management can facilitate appropriate and cost\u2010effective use of medicines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14393","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T19:19:15Z","timestamp":1590779955000},"page":"406-413","source":"Crossref","is-referenced-by-count":5,"title":["Sacubitril\/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-0242","authenticated-orcid":false,"given":"Cormac","family":"Kennedy","sequence":"first","affiliation":[{"name":"Dept. Pharmacology and Therapeutics Trinity College Dublin, Trinity Centre for Health Sciences, St. James' Hospital  Dublin 8 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3070-2268","authenticated-orcid":false,"given":"Amelia","family":"Smith","sequence":"additional","affiliation":[{"name":"Dept. Pharmacology and Therapeutics Trinity College Dublin, Trinity Centre for Health Sciences, St. James' Hospital  Dublin 8 Ireland"},{"name":"Medicines Management Programme, Health Service Executive, St. James' Hospital  Dublin 8 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Doran","sequence":"additional","affiliation":[{"name":"Dept. Pharmacology and Therapeutics Trinity College Dublin, Trinity Centre for Health Sciences, St. James' Hospital  Dublin 8 Ireland"},{"name":"Medicines Management Programme, Health Service Executive, St. James' Hospital  Dublin 8 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barry","sequence":"additional","affiliation":[{"name":"Dept. Pharmacology and Therapeutics Trinity College Dublin, Trinity Centre for Health Sciences, St. James' Hospital  Dublin 8 Ireland"},{"name":"Medicines Management Programme, Health Service Executive, St. James' Hospital  Dublin 8 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_2_11_3_1","unstructured":"European Medicines Agency.Entresto European Public Assessment Report 2015. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/entresto"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.1747"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0057"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.10.015"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.919"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2018.1478539"},{"key":"e_1_2_11_9_1","unstructured":"National Centre for Pharmacoeconomics.Cost\u2010effectiveness of Sacubitril\/Valsartan (Entresto) for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction2016. Available from:http:\/\/www.ncpe.ie\/wp-content\/uploads\/2015\/12\/Summary-v1-0-7.pdf"},{"key":"e_1_2_11_10_1","unstructured":"Health Services Executive\u2010Medicines Management Program.Sacubitril\/Valsartan (Entresto) Clinical and Reimbursement Information2017. Available from:https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/ncps\/medicines-management\/prescribing-tips-and-tools\/tips-and-tools-for-entresto.pdf"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.788"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1442090"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12258"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005400"},{"key":"e_1_2_11_15_1","unstructured":"PCRS Annual Report.Health Services Executive;2018."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.02.016"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000473"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-018-6830-x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.025"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0710-4"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.004815"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvw016"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.244"},{"key":"e_1_2_11_25_1","unstructured":"Novartis.Entresto Summary of Product Characteristics2019. Available from:https:\/\/www.medicines.ie\/medicines\/entresto-24mg-26mg-49mg-51mg-and-97mg-103mg-film-coated-tablets-32015\/smpc"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.018"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1512750"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.7661"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1515068"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:43:47Z","timestamp":1693212227000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/bcp.14393"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14393","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}